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OBJECTIVE — Continuous intraperitoneal insulin infusion (CIPII) with an implantable
pump has been available for the past 25 years. CIPII, with its speciﬁc pharmacodynamic prop-
erties, may be a viable treatment alternative to improve glycemic control in patients with type 1
diabetes for whom other therapies have failed. There have been few studies in which CIPII was
compared with subcutaneous insulin treatment for patients with type 1 diabetes with poor
glycemic control.
RESEARCH DESIGN AND METHODS — In an open-label, prospective, crossover,
randomized, 16-month study, the effects of CIPII and subcutaneous insulin were compared in
24 patients. The primary outcome measure was the incidence of hypoglycemia. Secondary
outcomemeasureswereA1C,andglucoseproﬁle,includingtimeineuglycemia,asmeasuredby
continuous glucose monitoring.
RESULTS — The incidence of grade 1 hypoglycemic events was 4.0  2.6 per week with
subcutaneous insulin compared with 3.5  2.3 per week during CIPII (P  0.13). The absolute
mean difference in A1C with CIPII compared with subcutaneous treatment was 0.76% (95%
CI 1.41 to 0.11) (P  0.03). Baseline time spent in euglycemia was 45.2  12.6% and
increased10.9%(4.6–17.3)withCIPIIcomparedwithsubcutaneoustreatment(absolutevalue;
P  0.003). There were no differences in the occurrence rate for severe hypoglycemic events,
daily insulin use, or BMI. No pump or catheter malfunction was observed during the study.
CONCLUSIONS — Although we did not observe a signiﬁcant reduction in hypoglycemic
events, improved glycemic control was achieved with the use of CIPII. We saw a 0.8% decrease
in A1C and an 11% increase in the time spent in euglycemia.
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M
eta-analysesconcludethatcontin-
uous subcutaneous insulin infu-
sion (CSII) is somewhat better
than multiple daily injections (MDIs) for
obtaining glycemic control in patients
with type 1 diabetes (1–4). These dif-
ferences tend to be smaller when syn-
thetic insulin analogs are used. The
absorption of subcutaneous infused in-
sulin is inﬂuenced by many factors,
sometimes responsible for unexpected
hypo- and hyperglycemic events (5,6).
In some patients with type 1 diabetes,
this form of therapy does not yield ac-
ceptable and stable long-term glycemic
control (7).
The intraperitoneal administration of
insulin allows blood glucose values to
normalize more rapidly after a meal with
more predictable insulin proﬁles than
with subcutaneous insulin (8–10). Much
of the intraperitoneal insulin is absorbed
through the portal system, which more
closely mimics normal physiological ac-
tion, resulting in improved hepatic up-
take and lower peripheral plasma insulin
levels (11). Intraperitoneal insulin may
lead to improved glucagon secretion and
hepaticglucoseproductioninresponseto
hypoglycemia (12).
The effects of continuous intraperito-
neal insulin infusion (CIPII) in type 1 di-
abetes have been investigated in few
randomizedcontrolledtrials,andallwere
donebeforetheeraofrapidlyactinginsu-
lin analogs. The objective of our study
was to assess the safety and efﬁcacy of
CIPII compared with intensiﬁed subcuta-
neous insulin therapy in patients with in-
adequately controlled type 1 diabetes.
RESEARCH DESIGN AND
METHODS— Subjectswithtype1di-
abeteswithlowfastingC-peptideconcen-
trations (0.20 nmol/l) and intermediate
or poor glycemic control, deﬁned as A1C
7.5% and/or 5 incidents of hypogly-
cemia(4.0mmol/l)perweek,whowere
aged 18–70 years and treated with MDIs
or CSII, were eligible for the study. The
exclusioncriteriaincludedimpairedrenal
function(plasmacreatinine150mol/l
or glomerular ﬁltration rate as estimated
by the Cockcroft-Gault formula 50 ml/
min)(13);cardiacproblems(unstablean-
gina or myocardial infarction within the
previous 12 months or New York Heart
AssociationclassIIIorIVcongestiveheart
failure); insulin allergy; mental handi-
caps; current or past psychiatric treat-
ment for schizophrenia or a cognitive or
bipolar disorder; severe untreated prolif-
erative retinopathy; current use of oral
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sitated oral or systemic corticosteroid use
more than once in the previous 12
months; substance abuse other than nic-
otine; a history of cancer, excluding well-
differentiated thyroid carcinoma, breast
carcinoma without lymph node metasta-
ses, and skin carcinoma; and plans to en-
gage in activities that require going 25
feet below sea level.
The study has a crossover, random-
ized design and was conducted at a single
center (Isala Clinics, Zwolle, the Nether-
lands). The study consisted of four
phases: the qualiﬁcation phase, the ﬁrst
treatmentphase,thecrossoverphase,and
the second treatment phase. During the
3-monthqualiﬁcationphase,thepatients’
prestudy diabetic therapy was used to at-
tempt optimization of their glycemic con-
trol. The patients were then randomly
allocated to one of two groups, which dif-
feredonlyinthesequenceofthetwother-
apies. Randomization was performed in
blocks of four.
Insulin(U400semisynthetichumanin-
sulin of porcine origin; Hoechst [recently
sanoﬁ-aventis], Frankfurt, Germany) was
administered with an implanted pump
(MIP 2007C; Medtronic/Minimed,
Northridge, CA). The CIPII pump was
implanted under general anesthesia at the
startoftheCIPIIphaseinallsubjects.Fig-
ure 1 is a schematic representation of the
pump and its location. For subjects who
received subcutaneous insulin during the
second treatment phase, the CIPII pump
was ﬁlled with an inert ﬂuid at the end of
the ﬁrst treatment phase. Subcutaneous
insulin was delivered with either MDIs or
CSII, according to what was used before
the study.
Bothtreatmentphaseswere6months
in duration. A crossover phase of 4 weeks
wasinstitutedinbetweentominimizethe
carryover effects of CIPII. During the
crossover phase, insulin was adminis-
tered subcutaneously. After completion
of the trial, subjects were given the op-
tion of continuing with their preferred
mode of therapy.
Patients monitored their own glucose
levels (One Touch Ultra; LifeScan, Milpi-
tas, CA) four times every day (fasting, be-
fore meals, and bedtime) and seven times
daily 2 days per week (fasting, before and
after meals, and bedtime). If nocturnal
hypoglycemia was suspected, subjects
would perform an additional blood glu-
cosemeasurementbetween2:00and3:00
A.M. Furthermore, subjects recorded all
episodes of hypoglycemia grade 1, de-
ﬁned as glucose 4.0 mmol/l; grade 2,
deﬁned as glucose 3.5 mmol/l; and
grade 3, deﬁned as the patient requiring
third-party help and/or losing conscious-
ness or requiring intravenous glucose or
glucagon treatment. To limit the risk of
data-entry error, the data from the self-
monitored blood glucose meters were
downloaded to a computer during every
clinic visit.
Twice per month, the study subjects
were in contact with a nurse specializing
in diabetes, alternating telephone and
clinic visits. The subjects were in contact
with the medical team as necessary.
If the subject was using 40 IU s.c.
insulin per day before starting the CIPII
phaseofthestudy,hisorherstartingdose
was set at 90% of the prior subcutaneous
dose. Subjects using 40 IU s.c. insulin
received a starting dose of 80% of the
prior subcutaneous dose. Initially, the
dose was equally divided between a basal
rate(50%)andabolusbeforemeals.Dur-
ing all study visits, the seven-point glu-
cosereadingswereusedtoadjustthedose
regimen if necessary to achieve prepran-
dial glucose levels between 4.0 and 7.0
mmol/l and postprandial levels between
4.0 and 9.0 mmol/l.
The study was performed in accor-
dance with the Declaration of Helsinki.
Informed consent was obtained from all
patients, and the protocol was approved
by the medical ethics committee of the
Isala Clinics in Zwolle.
Measurements
Demographic and clinical parameters
were recorded at baseline. These data in-
cluded smoking and alcohol habits, year
of diagnosis of diabetes, the presence of
complications, any comorbidity, and
height and weight. The A1C level was
measured at baseline, at the end of the
qualiﬁcation phase, and at the start, at the
Figure 1—Schematic view of the position of the insulin pump and catheter in vivo.
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treatment phases with a Primus Ultra2
system using high-performance liquid
chromatography (reference value 4.0–
6.0%). In addition, 5- to 7-day 24-h
bloodglucoseproﬁleswererecordedwith
a continuous glucose monitoring (CGM)
system(Medtronic/Minimed,Northridge,
CA) at baseline, at the halfway point, and
at the end of both treatment phases. Time
spent in the hypoglycemic range was de-
ﬁned as the percentage of CGM recordings
4.0 mmol/l, time spent in euglycemic
range was deﬁned as the percentage of
CGMrecordingsfrom4.0to10.0mmol/l,
and time spent in hyperglycemic range
was deﬁned as the percentage of CGM re-
cordings 10.0 mmol/l.
Primary and secondary outcomes
The primary outcome was the incidence
of hypoglycemic episodes. The secondary
outcome was glycemic control (as indi-
cated by A1C levels). Other prespeciﬁed
outcomes included time spent in hypo-
glycemia, euglycemia, and hyperglyce-
mia; daily insulin usage; adverse events;
and device complications. Adverse events
of CIPII and device complications were
subdivided according to the following
categories: pump malfunction, including
catheterobstruction;pump-siteinfection,
deﬁned as a culture-proven infection in
the subcutaneous pocket of the insulin
pump; prolonged pain, deﬁned as pain at
the pump site, which lasted for 6 weeks
after surgery; cutaneous erosion of the
skin, deﬁned as redness with signs of im-
minent perforation of the overlying skin
atthepumpsite;andpostoperativehema-
toma, deﬁned as a swelling at the pump
site caused by (re)bleeding.
Statistical analysis
Theincidenceofhypoglycemiagrade1in
potentiallyeligiblepatientsatourclinicof
3.7  2.2 per week was used for sample
size calculation. To be able to detect a
30% decrease in hypoglycemic events
withapowerof0.80andatwo-sidedof
0.05, 34 patients would be needed. To
compensate for nonevaluable patients,
the initial goal was to enroll 40 patients.
Descriptive summaries included the
mean  SD or SEM for normally distrib-
uted variables and the median with the
interquartile range for other variables.
Time variables, such as times spent in the
different glycemic states, are presented as
absolute values. Normality was examined
using Q-Q plots. Planned analyses were
conductedtoaddressthestudyobjectives
as deﬁned, using a nominal signiﬁcance
level of 0.05. General linear models were
used to test differences, taking the order
of the two treatments into account. To
calculate the mean difference with a 95%
CI,theHills-Armitageapproachwasused
(14),whichaccountsforanyperiodeffect
(15). If assumptions for the general linear
modelswerenotmet,nonparametrictests
were used, without obtaining a 95% CI.
Statistical analyses were performed with
SPSS software (versions 15.0 and 16.0).
All reported P values are two sided.
RESULTS— Of 50 patients who were
screened, 25 entered the qualiﬁcation
phase,afterwhich1patientwasexcluded
as having attained acceptable glycemic
control. Therefore, 24 patients were ran-
domly assigned and started the ﬁrst treat-
ment phase between June 2006 and
March 2007; 12 patients were assigned to
start with subcutaneous insulin and 12
patients to start with CIPII during the
ﬁrst phase (supplementary Fig. 1, avail-
able in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc08-2340/DC1).
PatientcharacteristicsarelistedinTa-
ble 1. The mean age was 43.6  11.8
years, and the mean diabetes duration
was 22.6  10.6 years. The mean num-
bers of hypoglycemic events grades 1 and
2were4.02.7and2.71.9perweek,
respectively. The mean A1C level was
8.6  1.1%.
Onepatientwithdrewconsentduring
the ﬁrst treatment phase while receiving
CIPII because of admission to a psychiat-
ric hospital for a depressive disorder. The
patient chose to continue CIPII treatment
after withdrawal from the trial, as did all
the patients who completed the study.
Hypoglycemia
The rate of hypoglycemia grade 1 with
CIPII was 3.5  2.3 per week compared
with 4.0  2.6 per week during subcuta-
neous insulin treatment (mean difference
0.50, 95% CI 1.16 to 0.17) (Table 2).
The rate of hypoglycemia grade 2 was
2.3  1.7 per week with CIPII compared
Table 1—Baseline characteristics
All
Treatment mode in ﬁrst phase
CIPII
Subcutaneous
insulin
n 24 12 12
Male sex 11 (46) 6 (50) 5 (42)
Age (years) 43.6  11.8 43.3  11.9 43.9  12.2
Diabetes duration (years) 22.6  10.6 20.6  9.5 24.7  11.6
Current smoker (%) 5 (21) 2 (17) 3 (25)
Systolic blood pressure (mmHg) 138.5  21.8 141.5  20.2 135.5  23.7
Diastolic blood pressure (mmHg) 80.1  7.8 82.7  6.5 77.6  8.4
Body weight (kg) 81.5  15.7 81.3  18.0 81.8  13.9
BMI (kg/m
2) 26.4  4.7 26.3  5.3 26.4  4.3
Hypoglycemia during
qualiﬁcation phase (n/week)*
Grade 1 4.0  2.7 4.1  2.9 3.8  2.7
Grade 2 2.7  1.9 2.8  1.8 2.6  2.0
Time spent in glucose range (%)†
Hypoglycemia 8.1  7.7 7.2  6.9 9.0  8.6
Euglycemia 45.2  12.6 44.2  10.6 46.1  14.8
Hyperglycemia 46.7  18.0 48.6  15.2 44.9  20.9
A1C (%) 8.6  1.1 8.5  1.0 8.6  1.2
Previous mode of insulin therapy
CSII 20 (83) 11 (92) 9 (75)
MDI 4 (9) 1 (8) 3 (25)
Insulin dose during
qualiﬁcation phase (IU/day) 46.3 (35.5–70.2) 44.1 (35.8–80.0) 47.0 (35.1–56.2)
Data are n (%), means  SD, or median (interquartile range). *Hypoglycemia grade 1 is deﬁned as a blood
glucose value 4.0 mmol/l; hypoglycemia grade 2 is deﬁned as a blood glucose value 3.5 mmol/l. †Time
spent in hypoglycemia is deﬁned as the percentage of CGM recordings of 4.0 mmol/l, time spent in
euglycemia is deﬁned as the percentage of CGM recordings between 4.0 and 10.0 mmol/l, and time spent in
hyperglycemia is deﬁned as the percentage of CGM recordings 10.0 mmol/l.
Glycemic control with intraperitoneal insulin
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neous insulin treatment (mean difference
0.43, 0.89 to 0.04). Two episodes of
hypoglycemia grade 3 occurred during
CIPII treatment and ﬁve episodes during
subcutaneous treatment (all in a single
patient).
Glycemic control
A1C decreased with CIPII from 8.6  1.1
to 7.5  0.7% after 3 months and re-
mained stable at 6 months (7.5  0.9%).
Duringsubcutaneoustreatmenttherewas
no change in glycemic control (Fig. 2).
When the effect of the treatment order
was taken into account, A1C improved
0.76% (95% CI 1.41 to 0.11) with
CIPII compared with subcutaneous insu-
lin treatment (absolute values) (Table 2).
The effect of treatment order was 0.37
(0.28 to 1.02) after 6 months.
Glucose proﬁle (CGM recording)
The time spent in hypoglycemia was not
signiﬁcantly different between CIPII and
subcutaneoustreatment(2.0%,95%CI
5.4 to 1.3). However, the time spent in
euglycemia was 10.9% (4.6–17.3) more
with CIPII than with subcutaneous treat-
ment. Subjects spent 8.9% (16.7 to
1.1) time in hyperglycemia with CIPII
thanwithsubcutaneousinsulintreatment
(Table 2, Fig. 3).
Insulin usage and clinical
parameters
There were no signiﬁcant differences be-
tween CIPII and subcutaneous insulin
treatmentwithrespecttodailyinsulinus-
age and clinical parameters (Table 2).
Adverse events and device
complications
There were no incidences of intraperito-
neal pump or catheter malfunction. One
subject developed a postoperative pump
pocket hematoma requiring surgical
drainage, but neither insulin delivery nor
its action was affected. In three subjects,
prolonged pain occurred, which was suc-
cessfully treated with oral analgesics (n 
2) and relocation of the catheter (n  1).
Figure 2—Mean A1C (percentage) at baseline and during subcutaneous insulin therapy (gray
lines) and intraperitoneal insulin therapy (black lines). *P  0.05 between therapy groups (solid
lines). Dashed lines indicate A1C in the two treatment order groups; smallest dashes indicate
subcutaneous insulin ﬁrst and CIPII second group; larger dashes indicate CIPII ﬁrst and subcu-
taneous insulin second. The I bars represent SEM.
Table 2—Change per treatment mode and overall CIPII treatment effect
Change with treatment mode
Treatment effect adjusted
for treatment order* P CIPII
Subcutaneous
insulin
n 23 23
A1C (%) 0.73  1.25 0.05  0.54 0.76 (1.41 to 0.11) 0.03
Hypoglycemia grade 1 (n/week)†‡ 0.64  2.11 0.15  1.33 0.50 (1.16 to 0.17) 0.13
Hypoglycemia grade 2 (n/week) †‡ 0.49  1.68 0.07  1.07 0.43 (0.89 to 0.04) 0.07
Time spent in glucose range (%)†§
Hypoglycemia 3.0  6.2 1.3  8.3 2.0 (5.4 to 1.3) 0.22
Euglycemia 7.8  18.9 4.1  17.2 10.9 (4.6 to 17.3) 0.002
Hyperglycemia 4.7  22.0 5.4  19.5 8.9 (16.7 to 1.2) 0.03
Insulin dose (IU/day)† 0.5 (6.8 to 5.0) 0.3 (6.7 to 5.8) 0.57
Systolic blood pressure (mmHg)† 0.4  17.6 4.0  16.3 3.0 (2.6 to 8.7) 0.28
BMI (kg/m
2)† 0.4  1.2 0.2  0.9 0.4 (0.9 to 0.2) 0.18
DataforchangearemeanSDormedian(interquartilerange).*Datafortreatmenteffectaremeandifferences(95%CI)adjustedfortreatmentordercalculatedusing
the Hills-Armitage method (14). †Change from baseline is reported. ‡Hypoglycemia grade 1 is deﬁned as a blood glucose value 4.0 mmol/l; hypoglycemia grade
2 is deﬁned as a blood glucose value 3.5 mmol/l. §Time spent in hypoglycemia is deﬁned as the percentage of CGM recordings of 4.0 mmol/l, time spent in
euglycemia is deﬁned as the percentage of CGM recordings between 4.0 and 10.0 mmol/l, and time spent in hyperglycemia is deﬁned as the percentage of CGM
recordings 10.0 mmol/l.
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ceiving subcutaneous insulin, myocardial
ischemia was diagnosed in one patient
who was subsequently treated with coro-
nary artery bypass grafting. After an ex-
tension of the crossover phase, this
subject continued with the trial.
CONCLUSIONS — With CIPII there
wasnosigniﬁcantdecreaseinthenumber
of hypoglycemic events. Nevertheless,
treatment with CIPII did reduce A1C lev-
els by 0.76% compared with subcutane-
ous insulin (absolute value). The
improvement in A1C was accompanied
by increased time spent in euglycemia
and less time spent in hyperglycemia,
both without any increase in either daily
insulin dose or BMI. At the end of the
study, all patients opted to continue with
CIPII.
Haardt et al. (16) performed a ran-
domized study comparing CIPII in a
crossover manner with subcutaneous hu-
maninsulinbyMDIsinninepatientswith
type 1 diabetes (16). They reported a
1.3% difference in A1C levels after 6
months in favor of CIPII as well as a re-
duction in glucose variability and hypo-
glycemic episodes with CIPII treatment
(16). The only other randomized con-
trolled trial comparing CIPII with subcu-
taneous insulin in patients with type 1
diabetes (n  21) had a parallel design
and showed no difference in A1C levels
(17). Since these two studies were pub-
lished, insulin analogs with more physio-
logical proﬁles have become widely
available and when used in CSII improve
glycemic control (18–23). No random-
ized trial comparing regimens based on
insulin analogs with CIPII was published
previously. A 45-day retrospective open-
label trial in 14 patients with type 1 dia-
betes compared CIPII with CSII using
insulin Lispro and reported a 0.5% lower
average A1C with CIPII (24).
One major limitation of this study is
that because of budget constraints, we
were only able to include 24 patients in
our study, instead of the projected 40,
which severely reduced the statistical
power. Furthermore, four patients used
MDIsinsteadofCSIIinthecontrolphase,
which may have affected the results. An-
other possible source of bias that we tried
tominimizebyusingacrossoverdesignis
the inﬂuence of subject preferences and
expectations.
Taking recent price increases into ac-
count,itisnotlikelythattheCIPIIoption
will be cost-effective in the near future,
although a formal cost-beneﬁt analysis
has not been done. However, based on
ourresults,werecommendconsideration
of CIPII as a treatment option for those
patients with type 1 diabetes who fail to
achieve satisfactory glycemic control
with other intensive insulin treatment
regimens.
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